-Mary Ann Liebert, Inc. announces the appointment of Professors Charles Nichols, PhD and Peter Hendricks, PhD as co-Editors-in-Chief of Psychedelic Medicine, a new peer-reviewed hybrid journal launching in early 2023.
Publishing online and in print with open access options, Psychedelic Medicine will provide an authoritative, high-profile forum for groundbreaking original research papers in both the basic and clinical sciences, review articles, debate, and commentary. A preview issue of the Journal is planned for late 2022.
Charles Nichols, PhD is a Professor of Pharmacology at LSU Health Sciences Center in New Orleans and has been researching psychedelics for 25 years. He earned his bachelor’s degree at Purdue University and received his PhD at Carnegie Mellon University studying the developmental genetics of fruit fly eye and retina development. He performed his postdoctoral work at Vanderbilt University School of Medicine in the Department of Pharmacology researching serotonin 5-HT2 receptor neuropharmacology and psychedelics under the mentorship of Dr. Elaine Sanders-Bush.
Dr. Nichols’s research centers on the pharmacology of serotonin 5-HT2A receptors, and he and his laboratory have made several key discoveries throughout the years. These include the first study of the effects of psychedelics on gene expression in brain, identification of specific populations of cell types within the brain that directly respond to psychedelics, the development of animal experimental systems that recapitulate the long-lasting antidepressant effects of psilocybin for mechanistic study, and discovery of the potent and profound anti-inflammatory effects of psychedelics for potential treatment of diseases like asthma and cardiovascular disease, among others. His research comprises three main areas. 1) The receptor pharmacology of ligand interactions with the 5-HT2A receptor, and drug discovery and design, 2) the study of psychedelics and their effects in the CNS ranging from molecular/genetics to behavioral models in rodents and Drosophila, and 3) elucidation of the mechanisms of action of the potent anti-inflammatory effects of psychedelics in models of human inflammatory disease.
Professor Nichols is a founding member of the International Society for Research on Psychedelics (ISRP), and serves as the society’s current President-Elect, and North American Councilor for the International Society of Serotonin Research (ISSR).
https://www.miragenews.com/professors-charles-nichols-phd-and-peter-772522/
